Mercaptopurine
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB01033 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 98 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | myeloid leukemia | KG + DL |
| 2 | pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma | KG + DL |
| 3 | chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation | KG + DL |
| 4 | pulmonary blastoma | KG + DL |
| 5 | Hodgkins lymphoma | KG + DL |
| 6 | primary pulmonary lymphoma | KG + DL |
| 7 | small cell lung carcinoma | KG + DL |
| 8 | well-differentiated fetal adenocarcinoma of the lung | KG + DL |
| 9 | precursor lymphoblastic lymphoma/leukemia | KG + DL |
| 10 | acute lymphoblastic leukemia | KG + DL |
| 11 | rheumatoid arthritis | KG + DL |
| 12 | ganglioneuroblastoma (disease) | KG + DL |
| 13 | brachydactyly-syndactyly syndrome | KG + DL |
| 14 | blast phase chronic myelogenous leukemia, BCR-ABL1 positive | KG + DL |
| 15 | neuroblastoma | KG + DL |
| 16 | retroperitoneal neoplasm | KG + DL |
| 17 | vertebral anomalies and variable endocrine and T-cell dysfunction | KG + DL |
| 18 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | KG + DL |
| 19 | methylcobalamin deficiency type cblE | KG + DL |
| 20 | chronic lymphocytic leukemia/small lymphocytic lymphoma | KG + DL |
| 21 | bladder transitional cell carcinoma | KG + DL |
| 22 | obsolete Hodgkin’s granuloma | KG + DL |
| 23 | lymphoid neoplasm | KG + DL |
| 24 | classic Hodgkin lymphoma | KG + DL |
| 25 | neonatal jaundice | KG + DL |
| 26 | ectodermal dysplasia and immunodeficiency | KG + DL |
| 27 | classic Hodgkin lymphoma, lymphocyte-depleted type | KG + DL |
| 28 | unclassified myelodysplastic syndrome | KG + DL |
| 29 | specific granule deficiency | KG + DL |
| 30 | thymic epithelial neoplasm | KG + DL |
| 31 | classic Hodgkin lymphoma, mixed cellularity type | KG + DL |
| 32 | nodular lymphocyte predominant Hodgkin lymphoma | KG + DL |
| 33 | follicular lymphoma | KG + DL |
| 34 | Burkitt lymphoma | KG + DL |
| 35 | chronic myelogenous leukemia, BCR-ABL1 positive | KG + DL |
| 36 | Hodgkin’s lymphoma, mixed cellularity | KG + DL |
| 37 | 2q33.1 microdeletion syndrome | KG + DL |
| 38 | aregenerative anemia | KG + DL |
| 39 | Hodgkin’s lymphoma, lymphocytic-histiocytic predominance | KG + DL |
| 40 | severe congenital hypochromic anemia with ringed sideroblasts | KG + DL |
| 41 | refractory cytopenia of childhood | KG + DL |
| 42 | partial deletion of the long arm of chromosome 5 | KG + DL |
| 43 | Hodgkin’s paragranuloma | KG + DL |
| 44 | Hodgkin’s lymphoma, lymphocytic depletion | KG + DL |
| 45 | ALK-positive large B-cell lymphoma | KG + DL |
| 46 | classic Hodgkin lymphoma, nodular sclerosis type | KG + DL |
| 47 | systemic Epstein-Barr virus-positive T-cell lymphoproliferative disease of childhood | KG + DL |
| 48 | classic Hodgkin lymphoma, lymphocyte-rich type | KG + DL |
| 49 | lung mixed small cell and squamous cell carcinoma | KG + DL |
| 50 | small intestine lymphoma | KG + DL |
(Showing top 50 of 98 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.